333 related articles for article (PubMed ID: 28369619)
21. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
22. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
Ischenko I; Petrenko O; Hayman MJ
Oncotarget; 2015 Jun; 6(18):15814-27. PubMed ID: 26158412
[TBL] [Abstract][Full Text] [Related]
23. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex.
von Burstin J; Eser S; Paul MC; Seidler B; Brandl M; Messer M; von Werder A; Schmidt A; Mages J; Pagel P; Schnieke A; Schmid RM; Schneider G; Saur D
Gastroenterology; 2009 Jul; 137(1):361-71, 371.e1-5. PubMed ID: 19362090
[TBL] [Abstract][Full Text] [Related]
24. Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.
Beglyarova N; Banina E; Zhou Y; Mukhamadeeva R; Andrianov G; Bobrov E; Lysenko E; Skobeleva N; Gabitova L; Restifo D; Pressman M; Serebriiskii IG; Hoffman JP; Paz K; Behrens D; Khazak V; Jablonski SA; Golemis EA; Weiner LM; Astsaturov I
Clin Cancer Res; 2016 Dec; 22(24):6153-6163. PubMed ID: 27384421
[TBL] [Abstract][Full Text] [Related]
25. An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice.
Edderkaoui M; Chheda C; Soufi B; Zayou F; Hu RW; Ramanujan VK; Pan X; Boros LG; Tajbakhsh J; Madhav A; Bhowmick NA; Wang Q; Lewis M; Tuli R; Habtezion A; Murali R; Pandol SJ
Gastroenterology; 2018 Dec; 155(6):1985-1998.e5. PubMed ID: 30144430
[TBL] [Abstract][Full Text] [Related]
26. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y
PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic reprogramming-induced guanidinoacetic acid synthesis promotes pancreatic cancer metastasis and transcription-activating histone modifications.
Yang J; Ren B; Ren J; Yang G; Fang Y; Wang X; Zhou F; You L; Zhao Y
J Exp Clin Cancer Res; 2023 Jun; 42(1):155. PubMed ID: 37370109
[TBL] [Abstract][Full Text] [Related]
28. The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.
Kiweler N; Brill B; Wirth M; Breuksch I; Laguna T; Dietrich C; Strand S; Schneider G; Groner B; Butter F; Heinzel T; Brenner W; Krämer OH
Arch Toxicol; 2018 Jul; 92(7):2227-2243. PubMed ID: 29845424
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer.
Xiang XS; Li PC; Wang WQ; Liu L
Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188676. PubMed ID: 35016922
[TBL] [Abstract][Full Text] [Related]
30. Impact of Hybrid-polar Histone Deacetylase Inhibitor m-Carboxycinnamic Acid bis-Hydroxyamide on Human Pancreatic Adenocarcinoma Cells.
Kumar D; Sarma P; Bhadra MP; Tangutur AD
Anticancer Agents Med Chem; 2019; 19(6):750-759. PubMed ID: 30621566
[TBL] [Abstract][Full Text] [Related]
31. Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-κB pathway.
Liu X; Xiao XY; Shou QY; Yan JF; Chen L; Fu HY; Wang JC
J Ethnopharmacol; 2016 Dec; 193():538-545. PubMed ID: 27686271
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts.
Nguyen AH; Elliott IA; Wu N; Matsumura C; Vogelauer M; Attar N; Dann A; Ghukasyan R; Toste PA; Patel SG; Williams JL; Li L; Dawson DW; Radu C; Kurdistani SK; Donahue TR
Oncotarget; 2017 Mar; 8(12):19074-19088. PubMed ID: 27894105
[TBL] [Abstract][Full Text] [Related]
33. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
34. Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
Shao M; He L; Zheng L; Huang L; Zhou Y; Wang T; Chen Y; Shen M; Wang F; Yang Z; Chen L
Bioorg Med Chem Lett; 2017 Sep; 27(17):4051-4055. PubMed ID: 28765013
[TBL] [Abstract][Full Text] [Related]
35. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
37. BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo.
Kumar K; DeCant BT; Grippo PJ; Hwang RF; Bentrem DJ; Ebine K; Munshi HG
JCI Insight; 2017 Feb; 2(3):e88032. PubMed ID: 28194432
[TBL] [Abstract][Full Text] [Related]
38. HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer.
Stojanovic N; Hassan Z; Wirth M; Wenzel P; Beyer M; Schäfer C; Brand P; Kroemer A; Stauber RH; Schmid RM; Arlt A; Sellmer A; Mahboobi S; Rad R; Reichert M; Saur D; Krämer OH; Schneider G
Oncogene; 2017 Mar; 36(13):1804-1815. PubMed ID: 27721407
[TBL] [Abstract][Full Text] [Related]
39. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
40. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
